Borda-Rodriguez, Alexander and Huzair, Farah
Due to copyright restrictions, this file is not available for public download
Click here to request a copy from the OU Author.
|Google Scholar:||Look up in Google Scholar|
From novel H1N1 vaccines to improved retroviral treatments for persons with HIV/AIDS, novel health technologies have substantially improved health care in developed countries. Whereas in developing countries, major infectious diseases such as malaria, tuberculosis and HIV/AIDS as well as noncommunicable diseases (NCDs) remain prevalent, are the leading causes of death, and stand to benefit from postgenomics diagnostics enabled by data intensive Omics technologies [1-3]. Historically, aid to developing countries has been provided by governments and aid organizations for over 50 years in a number of forms that included the provision of health technologies, medicines, and training for health campaigns (e.g., immunization programs). However, despite decades of aid and the global health funding that keeps flowing, people are still dying. Indeed, little progress has been made towards eradicating poverty and improving healthcare access for the poor. In this editorial analysis, we argue that the benefits of pharmacogenomics and personalized medicine should be considered beyond a narrow focus on clinical medicine and in particular, in strategies of international development aid delivery in order to achieve greater effectiveness of global development aid.
|Item Type:||Journal Article|
|Copyright Holders:||2011 Bentham Science Publishers|
|Keywords:||aid effectiveness; Millennium Development Goals; Paris Declaration; partnerships; personalized medicine; pharmacogenomics|
|Academic Unit/Department:||Mathematics, Computing and Technology > Engineering & Innovation|
|Interdisciplinary Research Centre:||Innovation, Knowledge & Development research centre (IKD)|
|Depositing User:||Farah Huzair|
|Date Deposited:||02 Dec 2011 10:40|
|Last Modified:||12 Dec 2012 08:00|
|Share this page:|